<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337635</url>
  </required_header>
  <id_info>
    <org_study_id>CHW 10/146, GC 1169</org_study_id>
    <nct_id>NCT01337635</nct_id>
  </id_info>
  <brief_title>Vitamin D Deficiency and Atopic Dermatitis</brief_title>
  <official_title>Treatment Of Vitamin D Deficiency And Effect On Atopic Dermatitis Severity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital and Health System Foundation, Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atopic dermatitis is a chronic skin disease characterized by a defective skin barrier,
      inflammation, and increased propensity for skin infections. Vitamin D is a fat-soluble
      vitamin that is primarily acquired through local production in the skin after ultraviolet
      light exposure but can also be obtained through natural and supplemental dietary sources.
      This randomized controlled trial will examine the effects of vitamin D repletion on atopic
      dermatitis severity in patients with diagnosed deficiency. The investigators hypothesize that
      pediatric patients with moderate or severe atopic dermatitis and vitamin D deficiency will
      have improved cutaneous disease after treatment with high dose as compared to standard dose
      vitamin D.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not meeting enrollment goals.
  </why_stopped>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atopic Dermatitis Severity at the Completion of Treatment</measure>
    <time_frame>6 weeks</time_frame>
    <description>The SCORAD (Severity Scoring of Atopic Dermatitis) is a clinical measurement tool assessing the severity of atopic dermatitis. The range of SCORAD measurements is 0 (best possible outcome) - 103 (worst possible outcome). The primary study endpoint will be the SCORAD score at the end of the 6 week treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Restart Topical Steroids</measure>
    <time_frame>2 years</time_frame>
    <description>The time to restart topical steroids and the SCORAD score at time of restart will be secondary study endpoints.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Standard dose vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with cholecalciferol 400 IU daily at home.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with ergocalciferol 300,000 IU (6 capsules of 50,000 IU) as a single oral dose observed in clinic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks</description>
    <arm_group_label>Standard dose vitamin D</arm_group_label>
    <arm_group_label>High dose vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Serum 25-hydroxyvitamin D level &lt;20 ng/ml (&lt;50 nmol/L)

          -  Diagnosed with atopic dermatitis by a CHW pediatric dermatologist

          -  Age 1-18 years old

          -  Primary residence in Milwaukee County

          -  Moderate and severe atopic dermatitis (Severity Scoring of Atopic Dermatitis [SCORAD]
             score greater than 15)

          -  On clinic protocol treatment for their atopic dermatitis (desonide ointment twice
             daily for the face and groin, triamcinolone 0.1% ointment twice daily for other areas)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne Chiu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital and Health System Foundation, Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>MIlwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2010</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <results_first_submitted>September 16, 2014</results_first_submitted>
  <results_first_submitted_qc>April 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 8, 2015</results_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Yvonne Chiu</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Dose Vitamin D</title>
          <description>Treatment with cholecalciferol 400 IU daily at home.
Vitamin D: Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>High Dose Vitamin D</title>
          <description>Treatment with ergocalciferol 300,000 IU (6 capsules of 50,000 IU) as a single oral dose observed in clinic.
Vitamin D: Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Dose Vitamin D</title>
          <description>Treatment with cholecalciferol 400 IU daily at home.
Vitamin D: Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>High Dose Vitamin D</title>
          <description>Treatment with ergocalciferol 300,000 IU (6 capsules of 50,000 IU) as a single oral dose observed in clinic.
Vitamin D: Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.5" lower_limit="2" upper_limit="15"/>
                    <measurement group_id="B2" value="5.7" lower_limit="3" upper_limit="9"/>
                    <measurement group_id="B3" value="6.7" lower_limit="2" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Atopic Dermatitis Severity at the Completion of Treatment</title>
        <description>The SCORAD (Severity Scoring of Atopic Dermatitis) is a clinical measurement tool assessing the severity of atopic dermatitis. The range of SCORAD measurements is 0 (best possible outcome) - 103 (worst possible outcome). The primary study endpoint will be the SCORAD score at the end of the 6 week treatment period.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Vitamin D</title>
            <description>Treatment with cholecalciferol 400 IU daily at home.
Vitamin D: Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>High Dose Vitamin D</title>
            <description>Treatment with ergocalciferol 300,000 IU (6 capsules of 50,000 IU) as a single oral dose observed in clinic.
Vitamin D: Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Atopic Dermatitis Severity at the Completion of Treatment</title>
          <description>The SCORAD (Severity Scoring of Atopic Dermatitis) is a clinical measurement tool assessing the severity of atopic dermatitis. The range of SCORAD measurements is 0 (best possible outcome) - 103 (worst possible outcome). The primary study endpoint will be the SCORAD score at the end of the 6 week treatment period.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="3.5" upper_limit="22.2"/>
                    <measurement group_id="O2" value="35.1" lower_limit="29.9" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Restart Topical Steroids</title>
        <description>The time to restart topical steroids and the SCORAD score at time of restart will be secondary study endpoints.</description>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Dose Vitamin D</title>
          <description>Treatment with cholecalciferol 400 IU daily at home.
Vitamin D: Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>High Dose Vitamin D</title>
          <description>Treatment with ergocalciferol 300,000 IU (6 capsules of 50,000 IU) as a single oral dose observed in clinic.
Vitamin D: Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yvonne Chiu, MD</name_or_title>
      <organization>Medical College of Wisconsin</organization>
      <phone>414-955-2818</phone>
      <email>ychiu@mcw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

